Expectations trend
FY2028 · fiscal year ending 2028-01-31 · fmp
Phreesia, Inc. (PHR)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$12.71-3.57%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.65 → 0.66 EPS · FY ending Jan 31, 2028 · 8 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PHR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA target of $125M-$135M for FY 2027 | Adjusted EBITDA target is $125M-$135M for 2027. | Improving | Adjusted EBITDA falls below $125M in FY 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-01-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 14, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth and operating-efficiency story with a healthcare-sector tailwind, rather than a low-risk business. The multi-year view is intact, supported by strong recent financial performance, though management’s forecasting variability and a run of earnings misses leave the thesis exposed.
The valuation evidence is mixed: PHR is described as cheap versus peers, while a separate measure shows a 54% premium to peers. The model has low confidence, and the priced-in tag says expectations are justified with low fragility, so the evidence does not point to a clear expectations cushion.
Near term, revenue has grown and adjusted EBITDA has expanded, while restructuring helped operating income improve; management maintains its fiscal 2027 revenue and adjusted EBITDA goals. However, revenue guidance was cut because network solutions are variable, and recent earnings misses make the next report a meaningful risk.
The multi-year thesis depends on delivering the fiscal 2027 goals while sustaining margin gains and managing network-solutions variability. Near term, another guidance cut or continued weakening in jobs data could add pressure, while strong results and higher guidance from healthcare peers could support sector momentum.
Over the next 1 to 3 years, PHR’s operating progress supports an intact long-term thesis, but high risk and uneven earnings leave execution as the main test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Phreesia, Inc.'s published investment case. The stated target is Successful cost reduction aligned with business priorities. |
| Improving |
| Operating expenses do not decrease or align with priorities |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “Recent Developments Restructuring Plan On May 7, 2026, we implemented a restructuring plan (the “Plan”) intended to reduce operating expenses and better align the cost structure with our current business priorities.” “The Plan includes the elimination of approximately 220 positions, approximately half of which are contractor roles.” Delivery assessment Nov 4, 2026 |
Revenue growth to $510M-$520M for FY 2027 | A primary condition in Phreesia, Inc.'s published investment case. The stated target is $510M-$520M. | Intact | Revenue falls below $510M in FY 2027 | Revenue: $129.458M FY2027-Q2; GAAP. Published target: $510M-$520M. Annual target cannot be compared with a quarterly or TTM observation. Sep 3, 2026129,458,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “We expect revenue to be in the range of $510 million to $520 million.” “Fiscal Second Quarter Ended July 31, 2026 Highlights • Total revenue was $129.5 million in the quarter, up 10% year-over-year.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.65 → $0.66 · observed estimates
$0.54B → $0.54B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-25 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-26 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-27 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-28 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-29 | $0.65 | $538,454,198 | 8 / 13 |
| 2026-07-30 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-07-31 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-01 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-02 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-03 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-04 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-05 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-06 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-07 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-08 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-09 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-10 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-12 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-13 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-14 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-15 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-16 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-17 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-18 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-19 | $0.67 | $540,349,540 | 8 / 13 |
| 2026-08-20 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-21 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-22 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-23 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-24 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-25 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-26 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-27 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-28 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-29 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-30 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-08-31 | $0.67 | $540,349,534 | 8 / 13 |
| 2026-09-01 | $0.67 | $540,350,887 | 8 / 13 |
| 2026-09-02 | $0.67 | $540,350,887 | 8 / 13 |
| 2026-09-03 | $0.69 | $540,869,000 | 8 / 13 |
| 2026-09-04 | $0.65 | $536,030,442 | 8 / 13 |
| 2026-09-05 | $0.65 | $536,030,442 | 8 / 13 |
| 2026-09-06 | $0.65 | $536,030,442 | 8 / 13 |
| 2026-09-07 | $0.65 | $536,030,442 | 8 / 13 |
| 2026-09-08 | $0.65 | $536,030,442 | 8 / 13 |
| 2026-09-09 | $0.66 | $536,025,141 | 8 / 13 |
| 2026-09-10 | $0.66 | $536,479,653 | 8 / 12 |
| 2026-09-11 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-12 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-13 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-14 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-15 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-16 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-17 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-18 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-19 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-20 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-21 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-22 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-23 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-24 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-25 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-26 | $0.64 | $536,626,737 | 8 / 13 |
| 2026-09-27 | $0.64 | $536,626,737 | 8 / 12 |
| 2026-09-28 | $0.64 | $536,626,737 | 8 / 12 |
| 2026-09-29 | $0.65 | $536,415,794 | 8 / 12 |
| 2026-09-30 | $0.65 | $536,415,794 | 8 / 12 |
| 2026-10-01 | $0.65 | $536,415,794 | 8 / 12 |
| 2026-10-02 | $0.65 | $536,415,794 | 8 / 12 |
| 2026-10-03 | $0.65 | $536,415,794 | 8 / 12 |
| 2026-10-04 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-05 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-06 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-07 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-08 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-09 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-10 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-11 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-12 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-13 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-14 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-15 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-16 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-17 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-18 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-19 | $0.65 | $534,868,244 | 8 / 12 |
| 2026-10-20 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-21 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-22 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-23 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-24 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-25 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-26 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-27 | $0.64 | $535,041,805 | 8 / 12 |
| 2026-10-28 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-10-29 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-10-30 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-10-31 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-11-01 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-11-02 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-11-03 | $0.66 | $537,101,919 | 8 / 12 |
| 2026-11-04 | $0.66 | $537,101,919 | 8 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 8 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.